Pathogenesis of Warthin's Tumors: A Critical Synthesis of the Evidence

Warthin tumor (WT) is the second most common benign parotid neoplasm, and its reported incidence has risen over recent decades, with a narrowing male predominance that parallels tobacco exposure trends. Whether WT is a true clonal neoplasm or a metaplastic process remains contested. We synthesize contemporary evidence on WT pathogenesis into a unified framework and articulate its diagnostic implications.

Critical narrative synthesis. We searched PubMed/MEDLINE, Embase, and Web of Science from inception through May 16, 2026 for "Warthin tumor" and its synonyms combined with subtopic terms spanning pathogenesis, embryology, smoking, radiation, oncocytic and mitochondrial biology, cellular senescence, IgG4-related disease, viral association, clonality, malignant transformation, and synchronous neoplasia, with hand-searching of reference lists. No formal eligibility criteria, dual independent screening, or quantitative pooling were applied. Reporting follows the Scale for the Assessment of Narrative Review Articles (SANRA).

Three converging lines of evidence account for WT pathogenesis: (1) an anatomic-embryologic substrate unique to the late-encapsulating parotid, in which salivary ductal epithelium is entrapped within intraparotid lymph nodes; (2) extrinsic-stressor-induced cellular injury and oncocytic metaplasia driven by tobacco, ionizing radiation, IgG4-mediated inflammation, or age-related mitochondrial decline; and (3) a permissive lymphoid microenvironment derived from pre-existing nodal parenchyma and actively remodeled by epithelium-derived chemokines. Clonality testing of conventional WT has been polyclonal, no recurrent oncogenic driver has been identified, and CRTC1-MAML2 has been reattributed to misclassified mucoepidermoid carcinoma.

The available evidence favors conventional WT as a metaplastic-proliferative lesion of ductal epithelium entrapped within intraparotid lymph nodes and modulated by extrinsic stressors, rather than as a true clonal neoplasm. Whether a KRAS-mutant subset is genuinely neoplastic remains unresolved, since a single activating mutation does not by itself establish malignancy. The absence of a consistent oncogenic driver, the histologic heterogeneity of rare associated malignancies spanning multiple epithelial and lymphoid subtypes, and the synchronous occurrence of WT with oral and aerodigestive carcinomas favor a carcinogen-driven field effect over clonal progression.